You can buy or sell ImmunoGen and other stocks, options, ETFs, and crypto commission-free!
ImmunoGen, Inc. Common Stock, also called ImmunoGen, is a biotechnology company, which engages in discovering and developing antibody-drug conjugate therapies that meaningfully improve the lives of people with cancer. Read More Its product candidates include Mirvetuximab soravtansine, Coltuximab ravtansine, IMGN7779 and IMGN632. The company was founded in March 1981 and is headquartered in Waltham, MA.
52 Week High
52 Week Low
Seeking AlphaMay 17
ImmunoGen: Assessing The Possibility Of A Turnaround
There is an aplenty of cash to fund its highly interesting pipeline. Other molecules have an excellent chance of delivering good results. Altogether, ImmunoGen is an excellent turnaround prospect to reward investors. With better endpoint guidance for positive results, I believe that the new investigation will bear excellent outcomes. After all, ImmunoGen now realized that mirvetuximab works best for high folate-alpha expression. ImmunoGen shares recently tumbled due to a negative regulatory binary. Amid t...
ImmunoGen, Solid Biosciences and Insys lead Wednesday’s biotech losers
Shares of ImmunoGen Inc. led biotech’s losers on Wednesday, falling 38% in intraday trade after the company disclosed that the U.S. Food and Drug Administration had recommended it run a second Phase 3 trial of an ovarian cancer drug. A first Phase 3 trial of the biotech’s IMGN, +0.52% investigational drug, called mirvetuximab soravtansine, failed to show that patients on the therapy had better progression-free survival or overall survival than those on chemotherapy. Despite the disappointment, the company ...
Yahoo FinanceMay 15
ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer
WALTHAM, Mass.--(BUSINESS WIRE)-- Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Scroll to continue with content Ad Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Platinum-Sensitive Patients ImmunoGen, Inc., (IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announ...
Expected Jul 26, Pre-Market